HighGravityDataHumana — Jul 30, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000049071-25-000039
Showing in the filing
Adjusted (non-GAAP) EPS
“approximately $17.00”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 24
GAAP EPS for FY2025
“approximately $13.77”
Insurance segment benefit ratio for FY2025
“90.1 percent to 90.5 percent”
Individual Medicare Advantage membership (de… for FY2025
“up to 500,000 members”
CenterWell Primary Care FY 2025 net patient … for FY2025
“50,000 to 70,000”
Adjusted (non-GAAP) EPS for FY2025
“approximately $17.00”
Diluted earnings per share (EPS) - Adjusted … for FY2025
“approximately $17.00”
Diluted earnings per share (EPS) - GAAP for FY2025
“approximately $13.77”
Consolidated revenues for FY2025
“at least $128 billion”
Total Revenues Consolidated - GAAP for FY2025
“at least $128 billion”
Total Revenues - Insurance segment for FY2025
“GAAP: at least $123 billion”
Total Revenues - CenterWell segment for FY2025
“GAAP: at least $21.5 billion”
Total Revenues CenterWell segment - GAAP for FY2025
“$20.5 billion to $21.5 billion”
Change in year-end medical membership - Indi… for FY2025
“Decline of 'up to 500,000'”
Change in year-end medical membership - Grou… for FY2025
“Relatively flat”
Change in year-end medical membership - Medi… for FY2025
“Growth of approximately 200,000”
Change in year-end medical membership - Stat… for FY2025
“Growth within 175,000 to 250,000 range”
Operating Cost Ratio - Consolidated GAAP for FY2025
“11.3% to 11.7%”
Segment Results - Insurance segment income f… for FY2025
“$1.6 billion to $2.0 billion”
CenterWell segment income from operations - … for FY2025
“GAAP: $1.1 billion to $1.5 billion”
CenterWell segment income from operations - … for FY2025
“Non-GAAP: $1.3 billion to $1.7 billion”
Effective Tax Rate for FY2025
“GAAP: approximately 25.0%”
Weighted Avg. Share Count for Diluted EPS for FY2025
“approximately 121 million”
Cash flows from operations for FY2025
“GAAP: $2.4 billion to $2.9 billion”
Capital expenditures for FY2025
“approximately $650 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
” 2 FY 2025 Earnings Guidance Humana revises its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) to 'approximately $13.77' from 'approximately $14.68', while also increasing its Adjusted EPS guidance to 'approximately $17.00' from the previous guidance of 'approximately $16.25'. Additional FY 2025 guidance points are included on page 13 of this earnings release. Diluted earnings per share FY 2025 Guidance FY 2024 (a) GAAP approximately $13.77 $9.98 Amortization associated with identifiable intangibles 0.49 0.50 Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) 3.01 2.45 Value creation initiatives (b) 0.44 2.33 Impairment charges (b) 0.26 1.65 Impact of exit of employer group commercial medical products business — 1.19 Cumulative net tax impact (0.97) (1.89) Adjusted (non-GAAP) – FY 2025 projected (b); FY 2024 reported approximately $17.00 $16.21 Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations. Humana Consolidated Highlights Humana Inc. Summary of Results ($ in millions, except per share amounts) 2Q25 (a) 2Q24 (a) YTD 2025 (a) YTD 2024 (a) Revenues $32,388 $29,540 $64,500 $59,151 Revenues - Adjusted (non-GAAP) $32,388 $29,380 $64,500 $58,711 Pretax results $741 $918 $2,432 $1,932 Pretax results - Adjuste
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.